95377-69-8Relevant articles and documents
Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity
Ghanem, Nada M.,Farouk, Faten,George, Riham F.,Abbas, Safinaz E.S.,El-Badry, Ossama M.
, p. 565 - 576 (2018)
New imidazo[4,5-b]pyridine derivatives were designed, synthesized and screened for their anticancer activity against breast (MCF-7) and colon (HCT116) cancer cell lines. Nine compounds (I, II, IIIa, IIIb, IV, VI, VIIa, VIII, IX) showed significant activit
1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl] -urea derivatives as small molecule heparanase inhibitors
Pan, Weitao,Miao, Hua-Quan,Xu, Yong-Jiang,Navarro, Elizabeth C.,Tonra, James R.,Corcoran, Erik,Lahiji, Armin,Kussie, Paul,Kiselyov, Alexander S.,Wong, Wai C.,Liu, Hu
, p. 409 - 412 (2007/10/03)
A novel class of 1-[4-(1H-benzoimidazol-2-yl)-phenyl]-3-[4-(1H- benzoimidazol-2-yl)-phenyl]-ureas are described as potent inhibitors of heparanase. Among them are 1,3-bis-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea (7a) and 1,3-bis-[4-(5,6-dimethyl-1H-benzoimidazol-2-yl)-phenyl]-urea (7d), which displayed good heparanase inhibitory activity (IC50 0.075-0.27 μM). Compound 7a showed good efficacy in a B16 metastasis model.